Last updated: October 1, 2026
Delsym is a Reckitt-owned U.S. over-the-counter cough-relief brand built around dextromethorphan polistirex, an extended-release formulation of the cough suppressant dextromethorphan. Its commercial position depends more on brand equity, retail distribution, formulation differentiation, and advertising than on patent exclusivity. Reckitt does not separately disclose Delsym revenue, profit, or market share, so the brand’s financial trajectory can be assessed only through parent-company disclosures and OTC cough-category indicators.
What is Delsym and who owns the brand?
Delsym is an OTC cough suppressant marketed primarily in the United States. Its principal active ingredient is dextromethorphan polistirex, which is designed to provide cough relief for up to 12 hours.
| Item |
Delsym profile |
| Brand owner |
Reckitt |
| Primary ingredient |
Dextromethorphan polistirex |
| Drug category |
OTC antitussive |
| Main dosage forms |
Extended-release oral liquid; pediatric and adult presentations; other line extensions may vary by market |
| Primary market |
United States |
| Regulatory route |
OTC monograph-based marketing framework |
| Prescription requirement |
None for standard OTC products |
| Main competitors |
Robitussin, store-brand dextromethorphan, Mucinex DM, Vicks, Coricidin and combination cough products |
| Revenue disclosure |
Not separately reported by Reckitt |
Reckitt obtained Delsym through its acquisition of Adams Respiratory Therapeutics, a transaction that also expanded Reckitt’s position in consumer respiratory health. Reckitt reports Delsym within its broader consumer health portfolio rather than as a standalone operating segment.
How does Delsym generate revenue?
Delsym’s revenue model is based on repeat retail purchases, seasonal demand and premium pricing for extended-release delivery. The brand is sold through pharmacies, mass merchants, grocery stores, club retailers, e-commerce channels and healthcare-oriented retail outlets.
The main revenue drivers are:
- Respiratory seasonality. Cough and cold demand rises during fall and winter, although product sales also respond to regional outbreaks and changing illness patterns.
- Extended-release positioning. The 12-hour dosing message gives Delsym a product distinction over immediate-release dextromethorphan liquids.
- Brand recognition. Delsym competes as a branded alternative to private-label cough suppressants.
- Retail availability. Shelf placement and online search visibility influence conversion in a category with substantial substitution.
- Product-line breadth. Adult, children’s and flavored variants allow the brand to address multiple household users.
- Consumer advertising. Delsym’s commercial performance is sensitive to media spending and in-store promotion.
Delsym’s financial profile differs from a prescription drug. There is no publicly reported per-product prescription volume, reimbursement base or payer mix. Retail sell-through, promotional intensity and retailer inventory levels are the more relevant commercial variables.
What is the financial trajectory for Delsym?
Reckitt does not report Delsym net revenue, gross margin, advertising expenditure or operating profit separately. The company reports performance at broader category and business-unit levels, including consumer health brands and geographic markets. As a result, a defensible standalone revenue forecast cannot be calculated from public filings.
Reckitt’s consumer health results provide the relevant financial context. Delsym is exposed to the performance of the company’s self-care portfolio, which includes respiratory, pain relief, digestive health and other OTC brands. Brand-level performance can therefore be masked by growth or decline in larger products.
| Financial question |
Publicly available answer |
| Annual Delsym revenue |
Not separately disclosed |
| Delsym EBITDA or operating profit |
Not separately disclosed |
| Delsym market share |
Usually available only through proprietary retail panels |
| Delsym advertising spend |
Not separately disclosed |
| Delsym unit volume |
Not separately disclosed |
| Parent-company exposure |
Included in Reckitt consumer health reporting |
| Forecast confidence |
Moderate for category direction; low for standalone brand revenue |
The likely financial trajectory is mature rather than high-growth. The brand benefits from established consumer awareness and a differentiated dosing format, but it operates in a low-barrier OTC category where private-label products can copy the active ingredient and compete on price.
What market dynamics affect Delsym sales?
How important is seasonality?
Seasonality is a central variable. Sales typically strengthen during the U.S. cough-and-cold season and weaken during warmer months. The timing and severity of respiratory illness waves can produce significant year-to-year volatility.
Post-pandemic changes in respiratory behavior create mixed effects. Reduced workplace attendance can lower some transmission channels, while changes in school attendance, viral circulation and consumer stockpiling can produce sharp demand swings. Retailers may also adjust inventory more aggressively after periods of unusual demand.
How does private-label competition affect Delsym?
Private-label dextromethorphan products pose the most direct structural threat. The active pharmaceutical ingredient is widely available, the regulatory pathway is established, and many buyers view cough suppressants as functionally interchangeable.
Delsym can defend a price premium through:
- 12-hour dosing;
- recognizable branding;
- taste and product acceptability;
- pediatric positioning;
- packaging and dosing convenience;
- retail availability; and
- consumer trust during acute illness.
The risk is greatest when consumers trade down during inflationary periods or when retailers promote store-brand alternatives.
What is the impact of inflation and consumer trade-down?
OTC cough products are relatively inexpensive compared with prescription medicines, so absolute affordability is usually strong. Still, inflation can increase private-label substitution. Retailers may allocate more shelf space to their own brands, while branded manufacturers use promotions to preserve volume.
Delsym’s exposure is therefore divided between price elasticity and brand loyalty. A premium product can retain consumers when the perceived benefit of 12-hour dosing is clear. It can lose share when consumers prioritize price and select an immediate-release generic.
How does Delsym compare with competing cough medicines?
| Product or category |
Principal positioning |
Competitive relationship with Delsym |
| Robitussin DM |
Branded cough suppressant, often combined with guaifenesin |
Direct brand competitor; broader combination-product presence |
| Store-brand dextromethorphan |
Low-price immediate-release or extended-release products |
Strongest price competitor |
| Mucinex DM |
Dextromethorphan plus guaifenesin |
Competes for consumers seeking cough suppression with mucus relief |
| Vicks cough products |
Brand-led cough and cold portfolio |
Competes through household brand recognition and distribution |
| Coricidin |
Cough and cold products, including formulations for consumers with hypertension concerns |
Competes in selected symptom-management segments |
| Combination cold products |
Multi-symptom relief |
Can substitute for Delsym when consumers seek treatment beyond cough suppression |
Delsym has a narrower therapeutic proposition than combination products. That focus can help consumers seeking cough relief alone, but it limits cross-selling relative to broader respiratory portfolios.
What is the FDA regulatory status of Delsym?
Delsym is an OTC product regulated under the FDA’s nonprescription cough-and-cold framework. Dextromethorphan is recognized as an OTC antitussive active ingredient under FDA regulations governing oral cough and cold products, including 21 C.F.R. Part 341.
The product’s commercial claims must remain consistent with its labeling, active ingredient, dosage instructions, age restrictions and applicable FDA requirements. Children’s cough-and-cold products face heightened scrutiny because of dosing errors and safety concerns in younger children.
The FDA’s OTC monograph system changed after enactment of the Coronavirus Aid, Relief, and Economic Security Act, which created a more formal administrative order process for OTC monograph products. That change affects the regulatory framework but does not create prescription-drug-style market exclusivity for Delsym.
What patents protect Delsym?
Delsym’s core commercial protection is unlikely to depend on an unexpired composition-of-matter patent. Dextromethorphan is an old active ingredient, and the extended-release polistirex delivery concept has been commercially established for decades.
Potential intellectual-property layers include:
- formulation technology;
- polymer-drug complexes;
- manufacturing processes;
- product-specific labeling;
- trademarks;
- packaging trade dress; and
- confidential manufacturing know-how.
The important distinction is between patent protection and brand protection. A competitor may be able to market a dextromethorphan product without copying Delsym’s trademarks, packaging or proprietary manufacturing process. That leaves Delsym exposed to substitution even if some formulation-related rights remain enforceable.
Are Delsym patents listed in the Orange Book?
Delsym is an OTC product, not a conventional prescription NDA product with the same Orange Book listing structure used for prescription drugs. A standard Delsym product therefore should not be analyzed as if it had a typical Orange Book patent-and-exclusivity profile.
The commercial consequence is material: there is generally no branded prescription-drug-style Orange Book barrier that would force a generic applicant to resolve listed patents through a Paragraph IV certification before launch.
When does Delsym lose exclusivity?
Delsym’s core active ingredient and broad therapeutic use do not have meaningful modern exclusivity protection. Any historical formulation patents would have expiration dates that are generally remote relative to the current market. The remaining exclusivity is primarily:
- trademark exclusivity for the Delsym name;
- trade-dress protection;
- regulatory compliance and manufacturing know-how;
- retailer relationships; and
- consumer brand equity.
Delsym can lose market share without a formal “loss of exclusivity” event. OTC competitors can enter through monograph compliance, subject to FDA requirements, without waiting for a patent cliff.
Are there Paragraph IV challenges to Delsym?
A conventional Paragraph IV challenge is not the principal competitive mechanism for Delsym. Paragraph IV litigation applies to patents listed for approved prescription drug products in the FDA Orange Book. Delsym’s OTC monograph positioning does not create the same litigation pathway.
Competitors are more likely to compete through:
- monograph-compliant OTC products;
- private-label formulations;
- alternative extended-release technologies;
- trademark-cleared packaging;
- retailer agreements; and
- direct-to-consumer marketing.
This materially reduces the probability of a single, identifiable generic-launch event. Competition can enter incrementally through multiple retailers and brands.
What manufacturing and intellectual-property barriers exist?
Manufacturing barriers are moderate. Immediate-release dextromethorphan products are relatively straightforward to produce. Extended-release products require more process control, including consistent drug-polymer dispersion, dosage uniformity, stability and acceptable taste.
The practical barriers include:
- sourcing pharmaceutical-grade dextromethorphan;
- producing a consistent extended-release matrix or complex;
- meeting dissolution specifications;
- maintaining dose accuracy;
- complying with current good manufacturing practices;
- managing pediatric safety and packaging requirements; and
- securing large-scale retail distribution.
These barriers are meaningful but not equivalent to the manufacturing barriers for biologics, sterile injectables or complex inhalation products. A capable OTC manufacturer can potentially develop a competing product without relying on Delsym’s brand or exact formulation.
What litigation affects Delsym?
No major current patent litigation involving Delsym can be identified from the publicly available information base used for this analysis. Delsym is not known for an active Orange Book patent dispute comparable to litigation surrounding major prescription drugs.
Potential legal exposure is more likely to involve:
- advertising claims;
- product labeling;
- consumer class actions;
- manufacturing quality;
- dosing and child-safety allegations;
- trademark disputes; or
- retailer and channel issues.
The absence of a visible patent case does not eliminate product-liability or regulatory risk. OTC cough products are used by large consumer populations, and labeling or dosing events can generate disproportionate reputational and legal costs.
Are there biosimilar risks for Delsym?
There is no biosimilar risk. Delsym is a small-molecule OTC drug, not a biologic. Its competitive risk comes from generic and private-label substitution, not biosimilar approval under the Public Health Service Act.
What licensing deals affect Delsym?
Reckitt’s acquisition of Adams Respiratory Therapeutics is the principal publicly known transaction relevant to Delsym’s ownership history. No major current Delsym-specific licensing arrangement is publicly disclosed in Reckitt’s principal financial reporting.
Third-party manufacturing, distribution and retail arrangements may exist, but they are not reported with sufficient product-level detail to quantify their effect on Delsym economics.
How strong is the Delsym brand and patent estate?
The Delsym brand estate is stronger than its patent estate.
| Asset |
Relative strength |
Commercial significance |
| Delsym trademark |
High |
Protects brand identity and limits direct naming imitation |
| Consumer awareness |
Moderate to high |
Supports premium pricing and repeat purchase |
| 12-hour positioning |
Moderate |
Provides a clear consumer benefit |
| Core active ingredient patent protection |
Low |
Dextromethorphan is long established |
| Formulation patent protection |
Low to moderate |
Historical or process-specific rights may exist, but broad market blocking power is limited |
| Manufacturing know-how |
Moderate |
Can protect consistency and product quality |
| Retail distribution |
Moderate to high |
Shelf access is important in OTC self-care |
| Regulatory exclusivity |
Low |
OTC monograph products do not receive ordinary prescription exclusivity |
The estate can support a durable branded business, but it is unlikely to prevent competitive entry.
What generic launch risks exist for Delsym?
The main generic-launch risk is continuous share erosion rather than a single launch date. The most likely scenarios are:
| Scenario |
Market effect |
| Low-cost immediate-release entries |
Pressure on price-sensitive consumers |
| Private-label extended-release products |
Direct attack on Delsym’s dosing proposition |
| Retailer-owned branded alternatives |
Reduced shelf access and promotional leverage |
| Combination cough products |
Substitution among consumers treating multiple symptoms |
| Safety-driven labeling changes |
Potential reduction in pediatric demand or increased compliance costs |
| Strong Delsym advertising |
Supports premium pricing and protects share |
The highest-risk product would combine extended-release dosing, acceptable taste, competitive pricing and broad retail availability. Such a product would challenge Delsym’s key differentiator without needing to copy its trademark.
What is the commercial outlook for Delsym?
Delsym is likely to remain a durable but mature OTC brand. Its growth ceiling is constrained by category commoditization, low switching costs and limited regulatory barriers. Its defensive strengths are brand recognition, a simple dosing proposition and the ability to command shelf space through Reckitt’s consumer-health infrastructure.
The most relevant performance indicators are:
- U.S. retail dollar and unit share;
- branded versus private-label share;
- average selling price;
- promotional discounting;
- household penetration;
- repeat purchase rates;
- respiratory-season sell-through;
- online search and conversion;
- retailer distribution;
- product complaints and recalls; and
- Reckitt’s broader self-care growth.
A positive financial trajectory would require stable or rising retail share, successful price realization and disciplined promotional spending. Revenue growth driven only by price increases could conceal unit erosion. Conversely, modest revenue growth with stable units would indicate stronger brand health.
Key Takeaways
- Delsym is a Reckitt-owned OTC cough suppressant based on extended-release dextromethorphan polistirex.
- Reckitt does not disclose Delsym revenue, profit, unit volume or standalone market share.
- The brand’s economics are driven by seasonality, retail distribution, consumer awareness and its 12-hour dosing proposition.
- Patent protection is limited relative to prescription-drug franchises. Trademark, trade dress, manufacturing know-how and retail access are more important.
- Delsym is not a conventional Orange Book product and is not exposed to a typical Paragraph IV patent challenge.
- Generic and private-label competition can enter incrementally under the OTC regulatory framework.
- There is no biosimilar risk because Delsym is a small-molecule OTC product.
- The brand’s outlook is durable but mature, with the main financial risk coming from price-based substitution and retailer-owned alternatives.
FAQs
Is Delsym a prescription drug?
No. Standard Delsym products are sold over the counter and contain dextromethorphan polistirex for cough suppression.
Does Delsym have a patent-protected 12-hour formula?
The extended-release formulation may be supported by historical formulation patents, manufacturing know-how and trade secrets. Broad active-ingredient exclusivity is not a current barrier because dextromethorphan is an established compound.
Can generic manufacturers sell a 12-hour Delsym competitor?
Yes, subject to FDA requirements, labeling rules, manufacturing standards and any enforceable formulation or process rights. A competitor cannot use the Delsym trademark or confusingly similar trade dress.
Is Delsym more exposed to generic competition than a prescription cough medicine?
Yes. OTC consumers can substitute among branded, private-label and combination products without a prescription-switching process. Retailers can also promote store-brand alternatives directly.
Does Reckitt disclose Delsym sales in its annual report?
No. Reckitt reports at broader business-unit and geographic levels. Delsym’s standalone revenue and profit are not separately disclosed.
References
-
Food and Drug Administration. (2023). Over-the-counter monograph drugs. U.S. Department of Health and Human Services.
-
Food and Drug Administration. (2024). 21 C.F.R. Part 341: Cold, cough, allergy, bronchodilator, and antiasthmatic drug products for over-the-counter human use. U.S. Department of Health and Human Services.
-
Reckitt Benckiser Group plc. (2024). Annual report and financial statements 2023. Reckitt.
-
Reckitt. (2024). Delsym cough relief product information. Reckitt Consumer Health.
-
United States Congress. (2020). Coronavirus Aid, Relief, and Economic Security Act, Section 505G. 116th Congress.
-
U.S. Patent and Trademark Office. (2024). Patent and trademark public search resources. U.S. Department of Commerce.
